Saleem Tipu Faiz M, Santhanam Prasanna, Hamoudeh Eyad, Hassan Tamer, Faiz Saba
Division of Endocrinology, JCESOM, Marshall University Huntington, USA.
W V Med J. 2012 Mar-Apr;108(2):26-30.
We are presenting the clinical features, diagnostic work up and treatment of acromegaly caused by Growth hormone releasing hormone (GHRH) secreting neuroendocrine tumor (NECT) in a case of multiple endocrine neoplasia type 1 (MEN-1). A 36 year old man, known case of MEN-1 presented with acromegalic features. He has high IGF-1, GH and very high GHRH levels with a pancreatic head tumor and pituitary mass. He had high GHRH arteriovenous gradient across pancreatic tumor and underwent tumor resection, Post operative GHRH level fell dramatically. Tumor had high GHRH m-RNA level. Acromegalic patients with MEN-1 should be screened for ectopic GHRH secretion. Measurement of GHRH arteriovenous gradient across NECT or mRNA for GHRH in resected tumor can confirm the ectopic source. Treatment of choice is surgical resection of the tumor. Somatostatin analogue is an alternative because of its dual action in the pituitary gland and the NECT. Life long surveillance is needed as recurrence chance is high.
我们报告了一例1型多发性内分泌腺瘤病(MEN-1)中由生长激素释放激素(GHRH)分泌性神经内分泌肿瘤(NECT)引起的肢端肥大症的临床特征、诊断检查及治疗情况。一名36岁男性,已知患有MEN-1,出现肢端肥大症特征。他的胰岛素样生长因子-1(IGF-1)、生长激素(GH)水平升高,GHRH水平极高,伴有胰头肿瘤和垂体肿块。他的胰腺肿瘤两侧GHRH动静脉梯度较高,并接受了肿瘤切除术,术后GHRH水平大幅下降。肿瘤的GHRH信使核糖核酸(m-RNA)水平较高。患有MEN-1的肢端肥大症患者应筛查异位GHRH分泌情况。测量NECT两侧的GHRH动静脉梯度或检测切除肿瘤中的GHRH mRNA可确认异位来源。治疗的首选方法是手术切除肿瘤。由于生长抑素类似物对垂体和NECT具有双重作用,它是一种替代治疗方法。由于复发几率较高,需要进行终身监测。